Krsnaa Diagnostics Q1 FY26: The Rajasthan Deal That Could Double Revenues & Reshape Its Future

Here’s an analysis of Krsnaa Diagnostics Limited’s Q1 FY26 earnings, delving into what the latest figures and strategic moves mean for its future trajectory.

Krsnaa Diagnostics: A Snapshot of Q1 FY26 – The Rajasthan Catalyst and Retail Momentum

The Indian market has been a tale of two halves, with a strong Q1 rally giving way to a more cautious July. In this environment, investors are keenly scrutinizing earnings for signals of resilience and future growth. Krsnaa Diagnostics, a prominent player in the diagnostic services space, has just unveiled its Q1 FY26 results, reporting a robust 13% year-on-year (YoY) revenue growth and an even more impressive 19% YoY EBITDA growth. But beyond the headline numbers, a closer look reveals a strategic shift that could redefine its growth story.

Let’s dissect the performance and, more importantly, peer into the crystal ball for Krsnaa’s future earnings potential.

Unpacking the Growth Drivers: A Look at Krsnaa’s “Order Book”

For a company heavily reliant on Public-Private Partnership (PPP) contracts, new awards are akin to a robust order book for a manufacturing firm. And Krsnaa Diagnostics delivered a blockbuster this quarter.

The Rajasthan PPP contract award stands out as a truly transformative development. This isn’t just another contract; it’s a significant expansion of Krsnaa’s footprint:

• Mother Labs: Soaring from 33 to 42.
• Satellite Labs: Jumping from 117 to 135.
• Collection Centers: A massive surge from 1,200 to 1,335.

This expanded scope is projected to generate an eye-watering INR 300 crores to INR 350 crores on an annualized basis once fully operational. To put this in perspective, Krsnaa’s entire Q1 FY26 revenue was INR 1,930 million (INR 193 crores). The Rajasthan contract alone promises nearly double its current quarterly revenue annually, signaling a substantial step-change in scale.

While the implementation will take about 6 to 9 months, with material revenues flowing from FY27 onwards and full potential realized in 1.5 to 2 years, the long-term earnings visibility from this 5-year pathology project is immense. This substantial “order” underpins a strong growth trajectory for the coming fiscal years, positioning Krsnaa as a major beneficiary of government-led healthcare infrastructure development, a key domestic-growth theme in India.

Sales Performance: Navigating Headwinds with Strategic Pivots

Krsnaa reported INR 1,930 million in revenue for Q1 FY26, a commendable 13% YoY growth. This growth is a testament to the company’s ability to drive its core radiology and pathology segments, even while facing some operational churn.

The volume growth stood at around 4%, which was somewhat subdued. The primary culprit? The non-renewal of the BMC contract due to unfavorable financial viability. This highlights the importance of prudent contract evaluation, even if it impacts immediate volumes. However, the overall 13% revenue growth, despite the moderate volume increase, suggests improved price realization or a favorable mix shift, likely driven by the expanding retail footprint.

Segmental & Regional Insights:

• Retail Business (RPL): This is Krsnaa’s strategic pivot. Currently contributing 6% to overall revenues, it’s gaining strong momentum. The company is leveraging its existing PPP hubs for logistics and quality, aiming for 5-8% of revenue in 1-1.5 years and 18-20% in the next 2 years. This B2C focus, with its inherent cash-paying nature, is also improving working capital.
• Himachal Pradesh & Karnataka: While Karnataka experienced some procedural changes that impacted revenue, management indicated normalization and an overall non-significant impact on company numbers. Himachal Pradesh revenues remained stable and improved.

Despite the BMC headwind, Krsnaa’s sales performance looks promising, especially with the strategic shift towards higher-margin retail and the impending revenue boost from Rajasthan. This positions the company as a fast grower, adept at adapting its strategy to maintain momentum.

Key Business Metrics: Efficiency and Expansion in Focus

A deeper look into Krsnaa’s operational metrics reveals a mixed bag of strengths and areas for close monitoring.

• EBITDA: The company delivered INR 524 million in EBITDA, a 19% YoY growth, with margins expanding by 120 basis points to 27%. This clearly demonstrates strong operational leverage and cost leadership, crucial for a high-volume service business.
• Patient & Test Volumes: Serving 5 million patients and processing nearly 16 million tests, these figures underscore Krsnaa’s scale. While volume growth was 4%, the expanded network and upcoming projects promise an acceleration.
• Retail Touch Points: A phenomenal surge from 362 to 2,414 YoY in retail touch points illustrates the aggressive expansion strategy. This rapid build-out, leveraging existing PPP infrastructure, is key to the retail business achieving breakeven by the end of FY26.
• Cost of Material Consumed: An area to watch. This increased from 22% to 25% sequentially, impacting EBITDA by approximately 3%. This is attributed to the increasing pathology revenue mix. Management’s commitment to negotiating better prices will be critical to sustain current margin levels, especially with the influx of new pathology projects like Rajasthan.

The expansion of radiology (200+ CT/MRI centers post-completion) and the NABH accredited teleradiology hub further solidify Krsnaa’s structural advantages in scale and quality. Management’s expectation of better-than-industry-peers growth in utilization levels in coming quarters bodes well for operating leverage.

Earnings Performance: Profitability in the Growth Equation

Krsnaa Diagnostics reported a Profit After Tax (PAT) of INR 205 million, marking a solid 15% YoY increase, with an 11% margin. Earnings Per Share (EPS) grew by 14% to INR 6.25.

The healthy PAT growth, outpacing revenue growth, is a direct result of the impressive EBITDA margin expansion. This indicates effective cost management and operational efficiencies, a hallmark of a well-run “fast grower.” While other income contribution isn’t highlighted as a significant factor, the growth appears to be driven by core operational performance.

The trajectory from here looks strong. The Retail segment’s journey towards breakeven by year-end will be a positive catalyst, and the full impact of the Rajasthan contract from FY27 will provide a significant boost to the bottom line. This sustained earnings growth, backed by strategic expansion and operational rigor, positions Krsnaa as a fast grower with the potential to transition into a super grower as its large-scale projects mature.

Working Capital & Capital Expenditure: Fueling Future Growth

Efficient working capital management is crucial, especially in the PPP model with its inherent receivable cycles. Krsnaa’s receivables maintained at around 120 days is acceptable for its business model, and the company has shown positive changes by initiating collections of long-overdue payments from Himachal Pradesh and Karnataka. The ramp-up of the cash-paying retail business is also contributing positively to working capital improvement. This indicates diligent management of the cash conversion cycle.

The Capital Expenditure (CapEx) plans for the Rajasthan PPP contract are substantial, estimated at INR 200 crores to INR 250 crores. This is clearly growth CapEx, aimed at building out the extensive lab and collection center network. Management is prudently evaluating funding options, including internal accruals, debt, leasing, or reagent rental models, to ensure optimal capital deployment without excessively straining the balance sheet or diluting margins.

The gestation period for Rajasthan (material revenue from FY27, full potential in 1.5-2 years) means near-term CapEx will precede revenue, but the long-term returns are significant. Additionally, the Apulki partnership, which involves deploying diagnostic equipment in oncology hospitals, provides almost 30 years of revenue visibility at potentially better prices than existing PPPs. The first Apulki hospital in Pune is expected to commercialize operations in the “next couple of months.” This strategic CapEx outlay underpins Krsnaa’s long-term growth ambition.

The Verdict: A Fast Grower Poised for a Leap 🚀

Krsnaa Diagnostics delivered a commendable Q1 FY26, showcasing resilience and operational efficiency. While the 4% volume growth was modest, the 13% revenue and 19% EBITDA growth, coupled with margin expansion, demonstrate strong execution. The increase in the Cost of Material Consumed is a metric to watch, but management’s focus on negotiation suggests proactive management.

The real story, however, lies in the future-facing developments. The transformative Rajasthan PPP contract acts as a powerful catalyst, promising a significant uplift in revenue from FY27 onwards. Concurrently, the accelerating retail business is not just expanding reach but is also expected to break even by the end of FY26, adding another layer of profitable growth.

In the context of the Indian economy, which favors domestic-growth themes, Krsnaa Diagnostics stands out. Its focus on expanding healthcare access through a robust PPP model and an accelerating B2C retail presence aligns perfectly with the strong domestic demand narrative. While the initial CapEx for Rajasthan might temper near-term profitability slightly, the long-term earnings visibility and strategic positioning make Krsnaa a compelling fast grower, well-poised to make a significant leap towards becoming a super grower in the coming years.

Investors should closely monitor the execution of the Rajasthan project and the breakeven trajectory of the retail segment, as these will be critical determinants of Krsnaa’s accelerated growth story.

Join our Telegram for instant updates!